Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle
Open Access

Factors Associated with Rapid Progression to Endstage Kidney Disease in Lupus Nephritis

Konstantinos Tselios, Dafna D. Gladman, Cameron Taheri, Jiandong Su and Murray B. Urowitz
The Journal of Rheumatology September 2020, jrheum.200161; DOI: https://doi.org/10.3899/jrheum.200161
Konstantinos Tselios
The University of Toronto Lupus Program is funded in part by the University Health Network, Toronto General, and Toronto Western Research Foundation. K. Tselios, MD, PhD, D.D. Gladman, MD, FRCPC, C. Taheri, BHSc, J. Su, MB, MSc, M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre of Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. The authors declare no conflicts of interest. Address correspondence to Dr. M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 14, 2020.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Konstantinos Tselios
Dafna D. Gladman
The University of Toronto Lupus Program is funded in part by the University Health Network, Toronto General, and Toronto Western Research Foundation. K. Tselios, MD, PhD, D.D. Gladman, MD, FRCPC, C. Taheri, BHSc, J. Su, MB, MSc, M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre of Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. The authors declare no conflicts of interest. Address correspondence to Dr. M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 14, 2020.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dafna D. Gladman
Cameron Taheri
The University of Toronto Lupus Program is funded in part by the University Health Network, Toronto General, and Toronto Western Research Foundation. K. Tselios, MD, PhD, D.D. Gladman, MD, FRCPC, C. Taheri, BHSc, J. Su, MB, MSc, M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre of Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. The authors declare no conflicts of interest. Address correspondence to Dr. M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 14, 2020.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiandong Su
The University of Toronto Lupus Program is funded in part by the University Health Network, Toronto General, and Toronto Western Research Foundation. K. Tselios, MD, PhD, D.D. Gladman, MD, FRCPC, C. Taheri, BHSc, J. Su, MB, MSc, M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre of Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. The authors declare no conflicts of interest. Address correspondence to Dr. M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 14, 2020.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Murray B. Urowitz
The University of Toronto Lupus Program is funded in part by the University Health Network, Toronto General, and Toronto Western Research Foundation. K. Tselios, MD, PhD, D.D. Gladman, MD, FRCPC, C. Taheri, BHSc, J. Su, MB, MSc, M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre of Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada. The authors declare no conflicts of interest. Address correspondence to Dr. M.B. Urowitz, MD, FRCPC, University of Toronto Lupus Clinic, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, 399 Bathurst St. 1E-410B, Toronto, ON M5T 2S8, Canada. Email: m.urowitz@utoronto.ca. Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication August 14, 2020.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Murray B. Urowitz
  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective Lupus nephritis (LN) may lead to endstage kidney disease (ESKD) in 22% of patients over a period of 15 years, with the risk being particularly higher in diffuse proliferative forms. The rate of kidney function decline varies. However, a catastrophic course leading to ESKD within a few years from onset is uncommon. The aim of the present study was to assess the factors associated with rapid progression to ESKD in patients with LN.

Methods Patients from the Toronto Lupus Clinic with biopsy-proven LN at presentation and estimated glomerular filtration rate (eGFR) 60 mL/min/1.73 m2, who developed ESKD within 3 years were retrieved. Pathology reports were reviewed with particular emphasis on distinct histopathologic features. Demographic, clinical, laboratory, and therapeutic variables were also analyzed.

Results Ten patients (1.8% of the total LN population) developed ESKD within 3 years of diagnosis. Their mean age was 34.2 ± 7.3 years, mean time to ESKD 19.2 ± 12.4 months, initial eGFR 90.2 ± 24.9 mL/ min/1.73 m2, proteinuria 2.7 ± 1.04 g/24 h. The median rate of kidney function decline was > 43 mL/ min/1.73 m2/year. One patient had LN class III, 5 had LN class IV, 2 had membranous LN (class V), and another 2 had mixed IV/V. Moreover, 2 patients had extensive thrombotic microangiopathy, 1 collapsing glomerulonephritis, and 1 concomitant antiglomerular basement membrane (anti-GBM) nephropathy. Four patients showed no unusual kidney pathology; all of them had severe noncompliance (discontinued all medications to follow alternative treatment).

Conclusion Catastrophic progression to ESKD is uncommon in LN. The major associated factors are poor compliance and distinct histopathologic features such as thrombotic microangiopathy, collapsing glomerulopathy, and concomitant anti-GBM nephropathy.

PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 1
1 Jan 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Factors Associated with Rapid Progression to Endstage Kidney Disease in Lupus Nephritis
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Factors Associated with Rapid Progression to Endstage Kidney Disease in Lupus Nephritis
Konstantinos Tselios, Dafna D. Gladman, Cameron Taheri, Jiandong Su, Murray B. Urowitz
The Journal of Rheumatology Sep 2020, jrheum.200161; DOI: 10.3899/jrheum.200161

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Factors Associated with Rapid Progression to Endstage Kidney Disease in Lupus Nephritis
Konstantinos Tselios, Dafna D. Gladman, Cameron Taheri, Jiandong Su, Murray B. Urowitz
The Journal of Rheumatology Sep 2020, jrheum.200161; DOI: 10.3899/jrheum.200161
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Salivary Gland Focus Score Is Associated With Myocardial Fibrosis in Primary Sjögren Syndrome Assessed by a Cardiac Magnetic Resonance Approach
  • National Priorities for High-quality Rheumatology Transition Care for Youth in Canada
  • The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis: A Randomized, Double-blind, Placebo-controlled Feasibility Study
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire